Search results for "CIO"

showing 10 items of 25726 documents

Prognosis and cure of long-term cancer survivors: A population-based estimation.

2019

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.…

0301 basic medicineOncologyMaleCancer ResearchTime FactorsSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineCancer SurvivorsProstateNeoplasmsThyroid cancerOriginal Researcheducation.field_of_studyRelative survivalMortality rateMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosispopulation-based cancer registriemedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesiscancer cure Italy population-based cancer registries prevalence survivalFemaleCancer PreventionAdultmedicine.medical_specialtypopulation-based cancer registriesAdolescentPopulationprevalenceSocio-culturalelcsh:RC254-282survival03 medical and health sciencesYoung AdultLife ExpectancyInternal medicinemedicinepopulation‐based cancer registriesHumansRadiology Nuclear Medicine and imagingcancer cureeducationAgedEstimationbusiness.industryCancerModels Theoreticalmedicine.disease030104 developmental biologyLife expectancycancer cure; Italy; population-based cancer registries; prevalence; survivalbusinessCancer medicine
researchProduct

Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study

2017

Context The molecular subtype of breast tumours plays a major role in cancer prognosis and treatment options. Triple negative tumours (TN) carry the worst prognosis and affects most frequently women of low socioeconomic status (SES). Studies have shown that non-biologic factors, such as the socioeconomic status could have an influence on tumour biology. To this date no study has been done investigating this association in French women. The objective is to study the association between the SES and the molecular tumour subtype of breast cancer patients in the French county of Cote d’Or. This study benefits from the population data from the Cote d’Or breast cancer registry known for its strict…

0301 basic medicineOncologyMultivariate analysisReceptor ErbB-2Social Scienceslcsh:MedicineBiochemistryGeographical Locations0302 clinical medicineSociologyBreast TumorsMedicine and Health SciencesEthnicitiesMedicineFrench PeopleRegistrieslcsh:ScienceLymph nodeMultidisciplinaryMiddle AgedEuropemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleFranceResearch ArticleAdultmedicine.medical_specialtyBreast NeoplasmsContext (language use)03 medical and health sciencesBreast cancerDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosisHumansSocial StratificationSocioeconomic statusGynecologybusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesCancermedicine.diseaseHormonesPopulation based studyClinical trial030104 developmental biologyMetastatic TumorsSocioeconomic FactorsPeople and PlacesPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast ca…

2017

Abstract Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Resul…

0301 basic medicineOncologyReceptor ErbB-2chemistry.chemical_compoundErbB-20302 clinical medicineDose-intensityExemestane80 and overNeoplasm MetastasisFulvestrantAged 80 and overeducation.field_of_studyAdvanced breast cancer Dose-intensity Everolimus Fulvestrant Hormone-receptor positiveAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2; SurgeryGeneral MedicineMiddle AgedEverolimu030220 oncology & carcinogenesisAdvanced breast cancerFemaleAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; SurgeryReceptormedicine.drugAdultmedicine.medical_specialtyPopulationSocio-culturaleBreast NeoplasmsHormone-receptor positive03 medical and health sciencesBreast cancerAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2Internal medicinemedicineHumansEverolimusAdverse effecteducationAgedNeoplasm StagingGynecologyEverolimusFulvestrantbusiness.industryfungiCancermedicine.diseaseAndrostadienesClinical trial030104 developmental biologychemistrySurgerybusinessFollow-Up StudiesThe Breast
researchProduct

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

2016

Abstract Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-sp…

0301 basic medicineOncologySettore MED/42 - Igiene Generale E Applicata0302 clinical medicinemorphology80 and overStage (cooking)Aged 80 and overOvarian Neoplasmseducation.field_of_studyepidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and GynecologyObstetrics and Gynecologyepidemiology; histology; morphology; ovarian cancer; stage; survivalMiddle AgedTransitional cell carcinomaovarian cancerOncology030220 oncology & carcinogenesisClear cell carcinomaepidemiologyFemaleHumanAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturalesurvivalArticlehistology03 medical and health sciencesInternal medicinemedicineHumansovarian cancer epidemiology survival stage morphology histologyeducationepidemiology ; histology ; morphology ; ovarian cancer ; stage ; survivalCancer stagingAgedNeoplasm StagingGynecologybusiness.industryOvarian NeoplasmCancermedicine.diseasestageCancer registry030104 developmental biologyOvarian cancerbusiness
researchProduct

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab …

2018

Objective In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. Methods Patients with stage IIB–IV or high-risk (grade 3/clear-cell) stage I–IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc ex…

0301 basic medicineOncologymedicine.medical_specialtyNeoplasm ResidualPaclitaxelBevacizumabmedicine.medical_treatmentPopulationArticleCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansCytoreductive surgeryStage (cooking)educationNeoplasm StagingOvarian NeoplasmsChemotherapyeducation.field_of_studybusiness.industryHazard ratioObstetrics and GynecologyResidual diseasemedicine.diseaseCarboplatinBevacizumab030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemaleOvarian cancerbusinessmedicine.drug:Ciencias de la Salud::Oncología [Materias Investigacion]
researchProduct

Multi-criteria framework as an innovative tradeoff approach to determine the shelf-life of high pressure-treated poultry

2016

International audience; A multi-criteria framework combining safety, hygiene and sensorial quality was developed to investigate the possibility of extending the shelf-life and/or removing lactate by applying High Hydrostatic Pressure (HHP) in a ready-to-cook (RTC) poultry product. For this purpose, Salmonella and Listeria monocytogenes were considered as safety indicators and Escherichia coli as hygienic indicator. Predictive modeling was used to determine the influence of HHP and lactate concentration on microbial growth and survival of these indicators. To that end, probabilistic assessment exposure models developed in a previous study (Lerasle, M., Guillou, S., Simonin, H., Anthoine, V.,…

0301 basic medicineOrganolepticHydrostatic pressureSodium lactateEscherichia-coliPoultrylLsteria-monocytogenesInactivationchemistry.chemical_compoundSalmonella[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceCookingPoultry ProductsPotassium lactateMathematics2. Zero hungerHigh hydrostatic-pressurePoultry product[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringRisk-risk trade-off;Lactate;Food hygiene;Food safety;Sensorial qualitySensorial qualityRisk-risk trade-off04 agricultural and veterinary sciencesGeneral Medicine040401 food scienceMeat ProductsCured beef carpaccioTasteIn-ground beefMeat-products030106 microbiologyShelf lifeMicrobiologyFood safety03 medical and health sciences0404 agricultural biotechnologyChicken meatFood PreservationEscherichia coliHydrostatic PressureFood hygieneFood microbiologyAnimalsHumansExposure assessmentbusiness.industryDifferent temperaturesFood safetyListeria monocytogeneschemistryFood StorageConsumer Product SafetyLactatebusinessFood Science
researchProduct

Fasciola spp: Mapping of the MF6 epitope and antigenic analysis of the MF6p/HDM family of heme-binding proteins

2017

MF6p/FhHDM-1 is a small cationic heme-binding protein which is recognized by the monoclonal antibody (mAb) MF6, and abundantly present in parenchymal cells and secreted antigens of Fasciola hepatica. Orthologs of this protein (MF6p/HDMs) also exist in other causal agents of important foodborne trematodiasis, such as Clonorchis sinensis, Opisthorchis viverrini and Paragonimus westermani. Considering that MF6p/FhHDM-1 is relevant for heme homeostasis in Fasciola and was reported to have immunomodulatory properties, this protein is expected to be a useful target for vaccination. Thus, in this study we mapped the epitope recognized by mAb MF6 and evaluated its antigenicity in sheep. The sequenc…

0301 basic medicineParagonimus westermaniFasciola sppPhysiologyProtein ConformationFlatwormslcsh:MedicineProtein Structure PredictionBiochemistryEpitopeAntigenicEpitopes0302 clinical medicineAnimal CellsImmune PhysiologyMedicine and Health SciencesMacromolecular Structure AnalysisMF6p/HDMEnzyme-Linked Immunoassayslcsh:ScienceMammalsNeuronsImmune System ProteinsMultidisciplinaryFasciolabiologyVaccinationEukaryotaAntibodies MonoclonalRuminantsDendritic StructureVertebratesCellular TypesAntibodyResearch ArticleHemeproteinsProtein StructureAntigenicityFascioliasisHeme bindingImmunology030231 tropical medicineAntibodies HelminthEnzyme-Linked Immunosorbent AssayHemeResearch and Analysis MethodsTrematodesAntibodiesHeme-Binding Proteins03 medical and health sciencesHelminthsparasitic diseasesParasitic DiseasesFasciola hepaticaAnimalsImmunoassaysMolecular BiologySheeplcsh:ROrganismsBiology and Life SciencesProteinsCell BiologyDendritesNeuronal DendritesFasciola hepaticabiology.organism_classificationInvertebratesMolecular biologyFasciola030104 developmental biologyEpitope mappingCellular NeuroscienceAntigens HelminthAmniotesImmunologic Techniquesbiology.proteinlcsh:QCarrier ProteinsEpitope MappingNeuroscience
researchProduct

On the presence and immunoregulatory functions of extracellular microRNAs in the trematode Fasciola hepatica.

2017

Summary Liver flukes represent a paraphyletic group of endoparasitic flatworms that significantly affect man either indirectly due to economic damage on livestock or directly as pathogens. A range of studies have focussed on how these macroscopic organisms can evade the immune-system and live inside a hostile environment such as the mammalian liver and bile-ducts. Recently, microRNAs, a class of short non-coding gene-regulators, have been proposed as likely candidates to play roles in this scenario. MicroRNAs (miRNAs) are key players in development and pathogenicity and are highly conserved between metazoans: identical miRNAs can be found in flatworms and mammalians. Interestingly, miRNAs a…

0301 basic medicinePathologymedicine.medical_specialtyFascioliasis030231 tropical medicineImmunologyGenomeHost-Parasite Interactions03 medical and health sciences0302 clinical medicineHepaticamicroRNAmedicineFasciola hepaticaAnimalsHumansDicrocoeliumImmune EvasionGeneticsbiologyHost (biology)Dicrocoelium dendriticumRNALiver flukeDicrocoeliasisFasciola hepaticabiology.organism_classificationMicroRNAs030104 developmental biologyLiverImmunologyParasitologyParasite immunology
researchProduct

Potential Influence of Helminth Molecules on COVID-19 Pathology

2020

In recent months, the parasitology research community has been tasked with investigation of the influence of parasite coinfection on coronavirus disease 2019 (COVID-19) outcomes. Herein, we share our approach to analyze the effect of the trematode Fasciola hepatica as a modulator of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of COVID-19 pathology.

0301 basic medicinePathologymedicine.medical_specialtyFascioliasisCoronavirus disease 2019 (COVID-19)Helminth proteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)viruses030231 tropical medicineInfection modulation03 medical and health sciences0302 clinical medicineAntigenic ModulationPathology modulationparasitic diseasesMedicineParasite hostingFasciola hepaticaHelminthsAnimalsHumansImmunologic FactorsInflammationHelminth parasitesRespiratory Distress SyndromebiologyForumbusiness.industryCoinfectionvirus diseasesCOVID-19Helminth ProteinsFasciola hepaticamedicine.diseasebiology.organism_classificationImmunity Innate030104 developmental biologyInfectious DiseasesParasitologyCoinfectionParasitologybusinessTrends in Parasitology
researchProduct

Quality of Life in Individuals with Diabetic Foot Syndrome.

2020

Background and Objective: Diabetic foot syndrome (DFS) is a common long-term complication of diabetes mellitus. DFS has recently been associated with adverse effects that could further impair the quality of life of diabetic patients, and increase the social and economic burden, morbidity, and premature mortality of the disease. The main physio-pathological basis of DFS is due to diabetesinduced neuropathy and angiopathy in the lower limbs and feet. Patients diagnosed with DFS must significantly modify their daily habits in order to cope with signs and symptoms of DFS and this can alter their quality of life. The objective of this review is to summarize the evidence regarding the economic, …

0301 basic medicinePediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseAmputation SurgicalAngiopathy03 medical and health sciences0302 clinical medicineQuality of lifeDiabetes mellitusSurveys and QuestionnairesDiabetes MellitusImmunology and AllergyMedicineHumansAdverse effectDepression (differential diagnoses)business.industrymedicine.diseaseDiabetic footDiabetic Foot030104 developmental biologySocioeconomic FactorsQuality of LifeHealth educationbusinessEndocrine, metabolicimmune disorders drug targets
researchProduct